CN1820789A - A kind of biodegradable hemostatic sponge material and preparation method thereof - Google Patents
A kind of biodegradable hemostatic sponge material and preparation method thereof Download PDFInfo
- Publication number
- CN1820789A CN1820789A CN 200610041913 CN200610041913A CN1820789A CN 1820789 A CN1820789 A CN 1820789A CN 200610041913 CN200610041913 CN 200610041913 CN 200610041913 A CN200610041913 A CN 200610041913A CN 1820789 A CN1820789 A CN 1820789A
- Authority
- CN
- China
- Prior art keywords
- collagen
- solution
- sponge material
- human
- hemostatic sponge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 27
- 239000000463 material Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 102000008186 Collagen Human genes 0.000 claims abstract description 41
- 108010035532 Collagen Proteins 0.000 claims abstract description 41
- 229920001436 collagen Polymers 0.000 claims abstract description 40
- 229920001661 Chitosan Polymers 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000012153 distilled water Substances 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 4
- 230000003472 neutralizing effect Effects 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 230000006196 deacetylation Effects 0.000 claims description 16
- 238000003381 deacetylation reaction Methods 0.000 claims description 16
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
- 108090000190 Thrombin Proteins 0.000 claims description 8
- 229960004072 thrombin Drugs 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract 2
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000001678 irradiating effect Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 4
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- -1 allyl acrylic acid Chemical compound 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种可生物降解止血海绵材料及其制备方法,属于生物医用材料领域。The invention relates to a biodegradable hemostatic sponge material and a preparation method thereof, belonging to the field of biomedical materials.
背景技术Background technique
外科手术及创伤中广泛出血和渗血是需要解决的难题。Extensive bleeding and oozing during surgery and trauma are difficult problems that need to be addressed.
胶原蛋白是动物体内含量最多、分布最广的蛋白质,是机体的主要结构蛋白,是支持组织和结缔组织的主要组分,它具有良好的生物相容性、止血性能、促新细胞形成功能和细胞粘附性。近年来的研究表明,胶原蛋白可在10秒钟内迅速止血,并可促进肉芽生长和伤口愈合,防止再次出血的发生。Collagen is the protein with the most content and widest distribution in animals. It is the main structural protein of the body and the main component of supporting tissue and connective tissue. It has good biocompatibility, hemostatic performance, and the function of promoting new cell formation and Cell Adhesion. Studies in recent years have shown that collagen can quickly stop bleeding within 10 seconds, promote granulation growth and wound healing, and prevent re-bleeding.
类人胶原蛋白是将人体已知序列胶原蛋白的一段mRNA逆转录生成cDNA后,经过特定序列重复和修饰,转化于大肠杆菌中,并经过高密度发酵、分离提取及纯化而得,由西安巨子生物基因技术股份有限公司发明并独家生产。它从根本上解决了动物提取胶原蛋白的水不溶性和病毒隐患(疯牛病、猪瘟疫、禽流感)等问题,并且具有良好的生物学特性和功能,促新细胞形成和促上皮细胞、成纤维细胞生长功能,相比动物体提取胶原蛋白优良,免疫排异反应低。Human-like collagen is obtained by reverse-transcribing a section of mRNA of collagen known in the human body to generate cDNA, then repeating and modifying specific sequences, transforming it into Escherichia coli, and undergoing high-density fermentation, separation, extraction and purification. It is produced by Xi'an Juzi Invented and exclusively produced by Biogene Technology Co., Ltd. It fundamentally solves the problems of water insolubility and virus hidden dangers (mad cow disease, swine plague, bird flu) extracted from animals, and has good biological characteristics and functions, promoting new cell formation and promoting epithelial cells, fibroblasts The growth function is better than the collagen extracted from animals, and the immune rejection is low.
甲壳素是从虾、蟹等甲壳类动物的外壳以及菌、藻类低等植物的细胞壁中提取出的天然高分子材料,壳聚糖是甲壳素的脱乙酰化产物,是自然界中唯一的碱性多糖。近年来的研究表明,壳聚糖具有止痛、止血、抑菌、良好的生物相容性和生物可降解性等优异的性能,非常适于作为止血材料的原料。Chitin is a natural polymer material extracted from the shells of crustaceans such as shrimps and crabs and the cell walls of lower plants such as bacteria and algae. Chitosan is the deacetylation product of chitin and is the only alkaline substance in nature. polysaccharides. Studies in recent years have shown that chitosan has excellent properties such as pain relief, hemostasis, bacteriostasis, good biocompatibility and biodegradability, and is very suitable as a raw material for hemostatic materials.
单纯明胶海绵或者胶原蛋白止血海绵的韧性较差,而且无止痛和抗菌效果,如中国专利CN200410022462.X和CN 01133795.8;单纯的壳聚糖海绵的促细胞生长和促组织恢复能力较弱,存在再次出血的可能。目前把两者结合起来的胶原蛋白-壳聚糖复合止血海绵可有效的克服以上缺点,如专利申请CN 02109638.4,但它同时存在病毒隐患以及促进伤口恢复缓慢的缺点。国际上对于止血海绵的研究也主要集中在胶原蛋白及其改性方面,如专利US 6649162,AU 726163B和RU 2122867,但是他们应用的都是传统的动物提取胶原蛋白,也不可避免的存在着病毒隐患,极大的限制了该止血海绵的应用。The toughness of simple gelatin sponge or collagen protein hemostatic sponge is relatively poor, and there is no analgesic and antibacterial effect, as Chinese patent CN200410022462. Possibility of bleeding. At present, the collagen-chitosan composite hemostatic sponge combined with the two can effectively overcome the above shortcomings, such as patent application CN 02109638.4, but it has the disadvantages of hidden virus and slow recovery of wounds. International research on hemostatic sponges also mainly focuses on collagen and its modification, such as patents US 6649162, AU 726163B and RU 2122867, but they all use traditional animal collagen extraction, and there are inevitably viruses Hidden danger greatly limits the application of this hemostatic sponge.
发明内容Contents of the invention
本发明的目的之一是提供一种将类人胶原蛋白和壳聚糖相结合的可生物降解的止血海绵材料,以克服明胶和动物胶原蛋白海绵所不可避免的病毒隐患,提高止血海绵材料的安全性。One of the purposes of the present invention is to provide a biodegradable hemostatic sponge material combining human-like collagen and chitosan, to overcome the inevitable virus hidden dangers of gelatin and animal collagen sponges, and to improve the safety of the hemostatic sponge material. safety.
本发明的另一目的是提供上述可生物降解的止血海绵材料的制备方法,该方法工艺简单。Another object of the present invention is to provide a method for preparing the above-mentioned biodegradable hemostatic sponge material, which has a simple process.
本发明的可生物降解止血海绵材料是由类人胶原蛋白和壳聚糖制成,类人胶原蛋白和壳聚糖的重量比可以为(1~40)∶1,最佳比例为(3~40)∶1,所用的类人胶原蛋白为使用基因重组大肠杆菌高密度发酵生产的一种人源型胶原蛋白;所用的壳聚糖的脱乙酰度为50%~90%。The biodegradable hemostatic sponge material of the present invention is made of human-like collagen and chitosan, the weight ratio of human-like collagen and chitosan can be (1~40): 1, and the optimal ratio is (3~ 40): 1, the human-like collagen used is a kind of human-derived collagen produced by high-density fermentation of recombinant Escherichia coli; the degree of deacetylation of the chitosan used is 50%-90%.
可生物降解止血海绵材材料的制备方法如下:(1)将类人胶原蛋白用蒸馏水溶解成0.5%~3%的溶液;(2)将壳聚糖用稀酸溶解成0.5%~2%的溶液,并使用碱中和;(3)将上述两种溶液混合均匀,经真空脱泡,冷冻干燥后形成海绵,钴60照射消毒后即可。The preparation method of the biodegradable hemostatic sponge material is as follows: (1) dissolving humanoid collagen into a 0.5% to 3% solution with distilled water; (2) dissolving chitosan into a 0.5% to 2% solution with dilute acid solution, and use alkali to neutralize; (3) the above two solutions are mixed uniformly, vacuum degassed, and freeze-dried to form a sponge, which can be sterilized by cobalt 60 irradiation.
上述制备方法中,类人胶原蛋白和壳聚糖的重量比为(1~40)∶1。所用的类人胶原蛋白为使用基因重组大肠杆菌高密度发酵生产的一种人源型胶原蛋白;所用的壳聚糖的脱乙酰化程度为50%~90%。In the above preparation method, the weight ratio of human-like collagen to chitosan is (1-40):1. The human-like collagen used is a kind of human-derived collagen produced by high-density fermentation of genetically recombined Escherichia coli; the degree of deacetylation of the chitosan used is 50% to 90%.
上述制备方法中,所用的稀酸为稀盐酸、稀醋酸、稀甲酸或稀丙酸中的任意一种,浓度可为0.2~0.8moL/L;所用的碱为稀氢氧化钠溶液、稀氢氧化钾溶液或碳酸氢钠溶液中的任意一种,浓度可为0.05~0.5moL/L。In the above-mentioned preparation method, the dilute acid used is any one of dilute hydrochloric acid, dilute acetic acid, dilute formic acid or allyl acrylic acid, and the concentration can be 0.2~0.8moL/L; The used alkali is dilute sodium hydroxide solution, dilute hydrogen Any one of potassium oxide solution or sodium bicarbonate solution, the concentration can be 0.05-0.5moL/L.
上述制备方法中,在类人胶原蛋白和壳聚糖混合溶液中还加入了重量百分比为0.1%~0.5%的增塑剂,所述的增塑剂为丙三醇或1.3-丁二醇中的一种或两种。In the above preparation method, a plasticizer of 0.1% to 0.5% by weight is added to the mixed solution of humanoid collagen and chitosan, and the plasticizer is glycerol or 1.3-butanediol one or both.
上述制备方法中,在类人胶原蛋白和壳聚糖混合溶液中还加入了重量百分比为0.1%~0.5%的凝血酶。In the above preparation method, 0.1%-0.5% of thrombin by weight is added to the mixed solution of humanoid collagen and chitosan.
本发明所提供的可生物降解止血海绵与现有技术相比,具有明显的技术优点和优势:该止血海绵与组织粘附性好,免疫排异反应低,韧性强,具有良好的止痛和抗菌性能,促进受伤组织恢复能力强,可防止再次出血的可能,彻底杜绝了明胶和动物胶原蛋白所不可避免的病毒隐患,使用安全性大幅度提高。Compared with the prior art, the biodegradable hemostatic sponge provided by the present invention has obvious technical advantages and advantages: the hemostatic sponge has good adhesion to tissues, low immune rejection, strong toughness, and good analgesic and antibacterial properties. It has a strong ability to promote the recovery of injured tissues, prevents the possibility of bleeding again, completely eliminates the inevitable virus hidden dangers of gelatin and animal collagen, and greatly improves the safety of use.
具体实施方式Detailed ways
下面通过具体实施实例对本发明作进一步说明。The present invention will be further described below through specific implementation examples.
实施例1:Example 1:
将类人胶原蛋白用蒸馏水溶解成1.0%的溶液;将脱乙酰度为90%、分子量为10000道尔顿的壳聚糖用0.2moL/L的醋酸溶解成0.5%的溶液,并使用0.1moL/L的碳酸氢钠溶液中和;然后将二者按体积比20∶1混合均匀,并加入0.2%的丙三醇,分装于容器中;经真空脱泡后冷冻干燥成2mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 1.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 90% and a molecular weight of 10,000 Daltons into a 0.5% solution with 0.2moL/L acetic acid, and use 0.1moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 20:1, add 0.2% glycerol, and pack them in containers; after vacuum defoaming, freeze-dry to form a 2mm thick sponge ; After cobalt 60 irradiation disinfection.
实施例2:Example 2:
将类人胶原蛋白用蒸馏水溶解成1.0%的溶液;将脱乙酰度为90%、分子量为10000道尔顿的壳聚糖用0.2moL/L的醋酸溶解成0.5%的溶液,并使用0.1moL/L的碳酸氢钠溶液中和;然后将二者按体积比10∶1混合均匀,并加入0.2%的丙三醇和0.3%的凝血酶,分装于容器中;经真空脱泡后冷冻干燥成2mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 1.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 90% and a molecular weight of 10,000 Daltons into a 0.5% solution with 0.2moL/L acetic acid, and use 0.1moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 10:1, add 0.2% glycerol and 0.3% thrombin, and pack them in containers; freeze-dry after vacuum defoaming Form a 2mm thick sponge; Cobalt 60 can be irradiated and sterilized.
实施例3:Example 3:
将类人胶原蛋白用蒸馏水溶解成2.0%的溶液;将脱乙酰度为90%、分子量为10000道尔顿的壳聚糖用0.2moL/L的醋酸溶解成1.0%的溶液,并使用0.1moL/L的碳酸氢钠溶液中和;然后将二者按体积比15∶1混合均匀,并加入0.2%的丙三醇,分装于容器中;经真空脱泡后冷冻干燥成1.5mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 2.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 90% and a molecular weight of 10,000 Daltons into a 1.0% solution with 0.2moL/L acetic acid, and use 0.1moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 15:1, add 0.2% glycerol, and pack in containers; after vacuum defoaming, freeze-dry to a thickness of 1.5mm Sponge; after cobalt 60 irradiation disinfection.
实施例4:Example 4:
将类人胶原蛋白用蒸馏水溶解成2.0%的溶液;将脱乙酰度为90%、分子量为10000道尔顿的壳聚糖用0.2moL/L的醋酸溶解成1.0%的溶液,并使用0.1moL/L的碳酸氢钠溶液中和;然后将二者按体积比8∶1混合均匀,并加入0.2%的丙三醇和0.2%的凝血酶,分装于容器中;经真空脱泡后冷冻干燥成1.5mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 2.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 90% and a molecular weight of 10,000 Daltons into a 1.0% solution with 0.2moL/L acetic acid, and use 0.1moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 8:1, add 0.2% glycerol and 0.2% thrombin, and pack them in containers; freeze-dry after vacuum defoaming Form a 1.5mm thick sponge; cobalt 60 can be irradiated and sterilized.
实施例5:Example 5:
将类人胶原蛋白用蒸馏水溶解成1.0%的溶液;将脱乙酰度为75%、分子量为100000道尔顿的壳聚糖用0.3moL/L的醋酸溶解成0.5%的溶液,并使用0.2moL/L的碳酸氢钠溶液中和;然后将二者按体积比10∶1混合均匀,并加入0.4%的1.3-丁二醇,分装于容器中;经真空脱泡后冷冻干燥成2mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 1.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 75% and a molecular weight of 100,000 Daltons into a 0.5% solution with 0.3moL/L acetic acid, and use 0.2moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 10:1, add 0.4% 1.3-butanediol, and pack them in containers; freeze-dry to a thickness of 2mm after vacuum defoaming Sponge; after cobalt 60 irradiation disinfection.
实施例6:Embodiment 6:
将类人胶原蛋白用蒸馏水溶解成1.0%的溶液;将脱乙酰度为75%、分子量为100000道尔顿的壳聚糖用0.3moL/L的醋酸溶解成0.5%的溶液,并使用0.2moL/L的碳酸氢钠溶液中和;然后将二者按体积比6∶1混合均匀,并加入0.4%的1.3-丁二醇和0.3%的凝血酶,分装于容器中;经真空脱泡后冷冻干燥成2mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 1.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 75% and a molecular weight of 100,000 Daltons into a 0.5% solution with 0.3moL/L acetic acid, and use 0.2moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 6:1, add 0.4% of 1.3-butanediol and 0.3% of thrombin, and pack them in containers; after vacuum defoaming Freeze-dried into a 2mm thick sponge; cobalt 60 irradiation disinfection can be done.
实施例7:Embodiment 7:
将类人胶原蛋白用蒸馏水溶解成2.0%的溶液;将脱乙酰度为75%、分子量为100000道尔顿的壳聚糖用0.3moL/L的醋酸溶解成1.0%的溶液,并使用0.2moL/L的碳酸氢钠溶液中和;然后将二者按体积比6∶1混合均匀,并加入0.4%的1.3-丁二醇,分装于容器中;经真空脱泡后冷冻干燥成1.5mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 2.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 75% and a molecular weight of 100,000 Daltons into a 1.0% solution with 0.3moL/L acetic acid, and use 0.2moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 6:1, add 0.4% 1.3-butanediol, and pack them in containers; freeze-dry to 1.5mm after vacuum defoaming Thick sponge; after cobalt 60 irradiation disinfection.
实施例8:Embodiment 8:
将类人胶原蛋白用蒸馏水溶解成2.0%的溶液;将脱乙酰度为75%、分子量为100000道尔顿的壳聚糖用0.3moL/L的醋酸溶解成1.0%的溶液,并使用0.2moL/L的碳酸氢钠溶液中和;然后将二者按体积比4∶1混合均匀,并加入0.2%的丙三醇,0.2%的1.3-丁二醇和0.2%的凝血酶,分装于容器中;经真空脱泡后冷冻干燥成1.5mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 2.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 75% and a molecular weight of 100,000 Daltons into a 1.0% solution with 0.3moL/L acetic acid, and use 0.2moL /L of sodium bicarbonate solution for neutralization; then mix the two evenly at a volume ratio of 4:1, and add 0.2% glycerol, 0.2% 1.3-butanediol and 0.2% thrombin, and pack them in containers Medium; freeze-dried into a 1.5mm thick sponge after vacuum defoaming; sterilized by cobalt 60 irradiation.
实施例9:Embodiment 9:
将类人胶原蛋白用蒸馏水溶解成1.0%的溶液;将脱乙酰度为55%、分子量为400000道尔顿的壳聚糖用0.5moL/L的盐酸溶解成0.5%的溶液,并使用0.1moL/L的氢氧化钠钠溶液中和;然后将二者按体积比5∶1混合均匀,并加入0.3%的丙三醇,分装于容器中;经真空脱泡后冷冻干燥成2mm厚的海绵;钴60照射消毒后即可。Dissolve humanoid collagen into a 1.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 55% and a molecular weight of 400,000 Daltons into a 0.5% solution with 0.5moL/L hydrochloric acid, and use 0.1moL /L of sodium hydroxide sodium solution for neutralization; then mix the two evenly at a volume ratio of 5:1, and add 0.3% glycerol, and pack them in containers; after vacuum degassing, freeze-dry into 2mm thick Sponge; after cobalt 60 irradiation disinfection.
实施例10:Example 10:
将类人胶原蛋白用蒸馏水溶解成1.0%的溶液;将脱乙酰度为55%、分子量为400000道尔顿的壳聚糖用0.5moL/L的盐酸溶解成0.5%的溶液,并使用0.1moL/L的氢氧化钠钠溶液中和;然后将二者按体积比2∶1混合均匀,并加入0.3%的丙三醇和0.3%的凝血酶,分装于容器中;经真空脱泡后冷冻干燥成2mm厚的海绵;钴60照射消毒后即可。Dissolve humanoid collagen into a 1.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 55% and a molecular weight of 400,000 Daltons into a 0.5% solution with 0.5moL/L hydrochloric acid, and use 0.1moL /L sodium hydroxide sodium solution for neutralization; then mix the two evenly at a volume ratio of 2:1, add 0.3% glycerol and 0.3% thrombin, and pack them in containers; freeze after vacuum defoaming Dried into a 2mm thick sponge; Cobalt 60 irradiation disinfection can be done.
实施例11:Example 11:
将类人胶原蛋白用蒸馏水溶解成2.0%的溶液;将脱乙酰度为55%、分子量为400000道尔顿的壳聚糖用0.5moL/L的盐酸溶解成1.0%的溶液,并使用0.1moL/L的氢氧化钠钠溶液中和;然后将二者按体积比3∶1混合均匀,并加入0.3%的丙三醇,分装于容器中;经真空脱泡后冷冻干燥成1.5mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 2.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 55% and a molecular weight of 400,000 Daltons into a 1.0% solution with 0.5moL/L hydrochloric acid, and use 0.1moL /L of sodium hydroxide sodium solution for neutralization; then mix the two evenly at a volume ratio of 3:1, add 0.3% glycerol, and pack in containers; freeze-dry to a thickness of 1.5mm after vacuum defoaming Sponge; after cobalt 60 irradiation disinfection.
实施例12:Example 12:
将类人胶原蛋白用蒸馏水溶解成2.0%的溶液;将脱乙酰度为55%、分子量为400000道尔顿的壳聚糖用0.5moL/L的盐酸溶解成1.0%的溶液,并使用0.1moL/L的氢氧化钠钠溶液中和;然后将二者按体积比1∶1混合均匀,并加入0.3%的丙三醇和0.3%的凝血酶,分装于容器中;经真空脱泡后冷冻干燥成1.5mm厚的海绵;钴60照射消毒后即可。Dissolve human-like collagen into a 2.0% solution with distilled water; dissolve chitosan with a deacetylation degree of 55% and a molecular weight of 400,000 Daltons into a 1.0% solution with 0.5moL/L hydrochloric acid, and use 0.1moL /L sodium hydroxide sodium solution for neutralization; then mix the two evenly at a volume ratio of 1:1, add 0.3% glycerol and 0.3% thrombin, and pack them in containers; freeze after vacuum defoaming Dried into a 1.5mm thick sponge; cobalt 60 can be irradiated and sterilized.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100419133A CN100415304C (en) | 2006-03-13 | 2006-03-13 | A kind of biodegradable hemostatic sponge material and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100419133A CN100415304C (en) | 2006-03-13 | 2006-03-13 | A kind of biodegradable hemostatic sponge material and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1820789A true CN1820789A (en) | 2006-08-23 |
CN100415304C CN100415304C (en) | 2008-09-03 |
Family
ID=36922458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100419133A Active CN100415304C (en) | 2006-03-13 | 2006-03-13 | A kind of biodegradable hemostatic sponge material and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100415304C (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028543B (en) * | 2007-04-03 | 2010-05-26 | 哈尔滨工业大学 | Degradable polyglycerol sebacate hemostatic sponge and preparation method thereof |
CN102258802A (en) * | 2010-05-28 | 2011-11-30 | 朱楚洪 | Novel multifunctional hemostatic dressing |
CN102526795A (en) * | 2012-02-15 | 2012-07-04 | 中国人民解放军广州军区武汉总医院 | Chitosan-based styptic sponge and preparation method thereof |
CN102600495A (en) * | 2011-01-19 | 2012-07-25 | 北京博恩康生物科技有限公司 | Absorbable hemostatic composition and preparation method thereof |
US9028872B2 (en) | 2006-03-01 | 2015-05-12 | Fmc Corporation | Gelled composite |
CN105903066A (en) * | 2016-07-02 | 2016-08-31 | 河南驼人贝斯特医疗器械有限公司 | Preparation method of absorbable and degradable in-vivo hemostatic sponge |
CN106512075A (en) * | 2016-12-02 | 2017-03-22 | 上海其胜生物制剂有限公司 | Preparation method of high-expansion lamella porous chitosan hemostatic sponge |
CN110368518A (en) * | 2019-03-19 | 2019-10-25 | 易杨华 | Rubidium salt styptic sponge and its application |
CN113842494A (en) * | 2021-09-10 | 2021-12-28 | 西北大学 | Injectable hemostatic crystal gel for promoting tissue regeneration and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
CN1234424C (en) * | 2001-09-10 | 2006-01-04 | 中国人民解放军军事医学科学院卫生装备研究所 | Collagen based composite sponge and production thereof |
CN1387922A (en) * | 2002-04-30 | 2003-01-01 | 岳武 | Quick-hemagglutination hemostasis sponge |
CN1217706C (en) * | 2003-08-22 | 2005-09-07 | 北京益而康生物工程开发中心 | Prepration process for biologic hemostatic sponge material |
-
2006
- 2006-03-13 CN CNB2006100419133A patent/CN100415304C/en active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9028872B2 (en) | 2006-03-01 | 2015-05-12 | Fmc Corporation | Gelled composite |
CN101028543B (en) * | 2007-04-03 | 2010-05-26 | 哈尔滨工业大学 | Degradable polyglycerol sebacate hemostatic sponge and preparation method thereof |
CN102258802A (en) * | 2010-05-28 | 2011-11-30 | 朱楚洪 | Novel multifunctional hemostatic dressing |
CN102258802B (en) * | 2010-05-28 | 2016-01-27 | 朱楚洪 | A kind of Novel multifunctional hemostatic dressing |
CN102600495A (en) * | 2011-01-19 | 2012-07-25 | 北京博恩康生物科技有限公司 | Absorbable hemostatic composition and preparation method thereof |
CN102526795A (en) * | 2012-02-15 | 2012-07-04 | 中国人民解放军广州军区武汉总医院 | Chitosan-based styptic sponge and preparation method thereof |
CN105903066A (en) * | 2016-07-02 | 2016-08-31 | 河南驼人贝斯特医疗器械有限公司 | Preparation method of absorbable and degradable in-vivo hemostatic sponge |
CN106512075A (en) * | 2016-12-02 | 2017-03-22 | 上海其胜生物制剂有限公司 | Preparation method of high-expansion lamella porous chitosan hemostatic sponge |
CN110368518A (en) * | 2019-03-19 | 2019-10-25 | 易杨华 | Rubidium salt styptic sponge and its application |
CN113842494A (en) * | 2021-09-10 | 2021-12-28 | 西北大学 | Injectable hemostatic crystal gel for promoting tissue regeneration and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100415304C (en) | 2008-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qin et al. | Development and application of fish scale wastes as versatile natural biomaterials | |
Singh et al. | Chitin and chitosan: biopolymers for wound management | |
Biswas et al. | Recent advancement of biopolymers and their potential biomedical applications | |
CN100376293C (en) | A method for preparing biodegradable scaffold material for tissue engineering | |
Azuma et al. | Preparation and biomedical applications of chitin and chitosan nanofibers | |
CN1820789A (en) | A kind of biodegradable hemostatic sponge material and preparation method thereof | |
CN1241657C (en) | Degradable material capable of guiding the regeneration and renovation process of hard tissue and its preparation | |
US8735571B2 (en) | Composition, preparation, and use of dense chitosan membrane materials | |
CN1220528C (en) | Carboxymethyl chitosan / carboxymethyl cellulose operative antiblocking film and method for making the same | |
Zhou et al. | Protocatechuic acid-mediated injectable antioxidant hydrogels facilitate wound healing | |
CN108912352A (en) | A kind of antibacterial adherency injection aquagel dressing and its preparation method and application | |
CN101695581A (en) | Method for preparing human-like collagen haemostatic sponge in scale | |
CN100582152C (en) | Method for preparing chitosan reinforced bars | |
CN1157568A (en) | Hard tissue irritant | |
CN104927348A (en) | Antibacterial and anticoagulant polymer material, preparation method and application thereof | |
WO2013096448A1 (en) | Composition, preparation, and use of dense chitosan membrane materials | |
CN1234424C (en) | Collagen based composite sponge and production thereof | |
Duan et al. | Multifunctional polysaccharide/metal/polyphenol double-crosslinked hydrogel for infected wound | |
CN110152055A (en) | Functional Drug Sustained-release Medical Dressing Constructed by Alginate Aminated Derivatives/Bacterial Cellulose Nanocrystal Composite Gel | |
CN1217706C (en) | Prepration process for biologic hemostatic sponge material | |
CN1539515A (en) | Biomaterial for preventing accretion after surgery and preparation method | |
CN1294994C (en) | Injectable type collagen-based soft tissue filling material and preparation method thereof | |
Zubair et al. | Emerging trends and challenges in polysaccharide derived materials for wound care applications: A review | |
CN104208741A (en) | Chitosan based adhesive bandage | |
CN116570758A (en) | Injectable antibacterial hydrogel that can be used for irregular wound repair and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |